Eph receptor tyrosine kinases bind membrane bound ligands (ephrins) to regulate a variety of processes, including embryonic pattern formation, angiogenesis, and axon guidance. The C. elegans genome encodes one Eph receptor, VAB-1, and four ephrins, EFN-1 to EFN-4. We showed previously that EFN-1 is a ligand for VAB-1 and functions in neurons to regulate epithelial and neuronal morphogenesis (Chin-Sang et al., Cell 99: 781). We reported previously that mutations in the
mab-26 gene, initially identified as a ray morphology mutant (Chow and Emmons, Development 120:2579), affect the fourth ephrin, EFN-4. Although VAB-1 encodes the only Eph receptor in the worm genome, several lines of evidence suggest that EFN-4 does not function only through the VAB-1 receptor. First, we tested whether cell-surface expressed EFN-4 binds VAB-1 using a soluble VAB-1-AP fusion protein as an affinity reagent. Our preliminary results suggest that the affinity of EFN-4 for VAB-1-AP is extremely low compared with the EFN-1/VAB-1 affinity. Second, the embryonic and larval phenotypes of
efn-4 mutants differ from those of
vab-1 and
efn-1 mutants, although they show some overlap (see abstract by Moseley and Chisholm). This overlap in phenotype is reflected in the
efn-4 expression pattern. Using EFN-4-GFP transgenes and anti-EFN-4 antibodies we have found that EFN-4 is expressed in the developing nervous system in a pattern that appears to overlap both VAB-1 and EFN-1 expression domains. Finally,
efn-4 alleles display strong synthetic lethality with either
vab-1 or
efn-1 mutations.
vab-1;
efn-4 double mutants display fully penetrant embryonic lethality, a phenotype that is stronger than the
vab-1 null phenotype. These data are inconsistent with
efn-4 acting exclusively in a VAB-1 dependent pathway and suggest that EFN-4 may act independently of the VAB-1 receptor. To identify genes that may be involved in this independent pathway we have begun suppressor screens of the
vab-1;
efn-4 synthetic lethality and have also screened for mutations that show synthetic lethality with weak
vab-1 alleles. Characterization of our suppressors and enhancers will be presented.